SCHEMBL5230902

SCHEMBL5230902

CCOC(=O)c1cn(-c2ccc(CO)cc2)nc1N(C(=O)C1CCC(C)CC1)C(C)C

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 7/20 0.38
RAB9A P51151 7/20 0.38
ALDH1A1 P00352 4/20 0.38
NPSR1 Q6W5P4 4/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
GLA P06280 1/20 0.38
NFKB1 P19838 1/20 0.38
NFKB2 Q00653 1/20 0.38
RELA Q04206 1/20 0.38
CA12 O43570 5/20 0.38
CA9 Q16790 5/20 0.38
MAPK1 P28482 2/20 0.37
KDM4E B2RXH2 2/20 0.36
KMT2A Q03164 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
CYP1A2 P05177 1/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2D6 P10635 1/20 0.35
CYP2C9 P11712 1/20 0.35
CYP2C19 P33261 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5230892 1.00 NPC1 (0.38) NPC1RAB9AALDH1A1NPSR1SMN1; SMN2
SCHEMBL5238262 0.95 NPC1 (0.39) NPC1RAB9AALDH1A1NPSR1SMN1; SMN2
SCHEMBL5238271 0.95 NPC1 (0.39) NPC1RAB9AALDH1A1NPSR1SMN1; SMN2
SCHEMBL5232482 0.92 RAB9A (0.38) NPC1RAB9AALDH1A1NPSR1SMN1; SMN2
SCHEMBL5232491 0.92 RAB9A (0.38) NPC1RAB9AALDH1A1NPSR1SMN1; SMN2
SCHEMBL5652334 0.92 RAB9A (0.46) NPC1RAB9AALDH1A1NPSR1SMN1; SMN2
SCHEMBL5652329 0.92 RAB9A (0.46) NPC1RAB9AALDH1A1NPSR1SMN1; SMN2
SCHEMBL5232093 0.91 NPC1 (0.39) NPC1RAB9AALDH1A1NPSR1SMN1; SMN2
SCHEMBL5232099 0.91 NPC1 (0.39) NPC1RAB9AALDH1A1NPSR1SMN1; SMN2
SCHEMBL5235387 0.90 NPC1 (0.46) NPC1RAB9AALDH1A1NPSR1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1730116-B1 4-CARBOX PYRAZOLE DERIVATES USEFUL AS ANTI-VIRAL AGENTS SMITHKLINE BEECHAM CORP (US) 2007-09-05 EP disclosed
US-20070167507-A1 4-Carbox pyrazole derivatives useful as anti-viral agents GLAXO GROUP LIMITED (GB) 2007-07-19 US disclosed
EP-1730116-A1 4-CARBOX PYRAZOLE DERIVATES USEFUL AS ANTI-VIRAL AGENTS SMITHKLINE BEECHAM CORPORATION (US) 2006-12-13 EP disclosed
WO-2005092863-A1 4-CARBOX PYRAZOLE DERIVATES USEFUL AS ANTI-VIRAL AGENTS SMITHKLINE BEECHAM CORPORATION (US) 2005-10-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070167507-A1 4-Carbox pyrazole derivatives useful as anti-viral agents HAVCR2, RPL35, ZC3HAV1L NPC1 352/4885RAB9A 1879/4885ALDH1A1 1138/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.